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X-linked nephrogenic diabetes insipidus (X-NDI) is a disease
caused by inactivating mutations of the vasopressin (AVP)
type 2 receptor (V2R) gene. Loss of V2R function prevents
plasma membrane expression of the AQP2 water channel in
the kidney collecting duct cells and impairs the kidney
concentration ability. In an attempt to develop strategies to
bypass V2R signaling in X-NDI, we evaluated the effects of
secretin and fluvastatin, either alone or in combination, on
kidney function in a mouse model of X-NDI. The secretin
receptor was found to be functionally expressed in the
kidney collecting duct cells. Based on this, X-NDI mice were
infused with secretin for 14 days but urinary parameters
were not altered by the infusion. Interestingly, secretin
significantly increased AQP2 levels in the collecting duct but
the protein primarily accumulated in the cytosol. Since we
previously reported that fluvastatin treatment increased
AQP2 plasma membrane expression in wild-type mice,
secretin-infused X-NDI mice received a single injection of
fluvastatin. Interestingly, urine production by X-NDI mice
treated with secretin plus fluvastatin was reduced by nearly
90% and the urine osmolality was doubled. Immunostaining
showed that secretin increased intracellular stores of AQP2
and the addition of fluvastatin promoted AQP2 trafficking to
the plasma membrane. Taken together, these findings open
new perspectives for the pharmacological treatment of
X-NDI.
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The most recurrent genetic defects associated with hereditary
nephrogenic diabetes insipidus (NDI) are the inactivating
mutations of the vasopressin (AVP) receptor type 2 (V2R)
gene that are localized on the X chromosome.1–3 AVP binding
to the V2R stimulates the trafficking of the aquaporin 2
(AQP2) water channel to the apical membrane of the collect-
ing duct (CD) principal cells and also promotes AQP2
transcription.4–10 Upon release into the systemic circulation,
AVP (V2R) activates adenylyl cyclase, increases intracellular
cyclic adenosine monophosphate (cAMP) levels, activates
protein kinase A and other kinases, and phosphorylates
AQP2. These events cause both the translocation of AQP2
storage vesicles to the apical plasma membrane and slow
down AQP2 endocytic retrieval,11 thus promoting water
reabsorption in the CD.6 In addition, V2R activation pro-
motes phosphorylation of the cAMP-responsive element-
binding protein and the expression of c-Fos. Binding of these
factors to CRE and AP1 sites leads to AQP2 promoter
activation.12 Owing to the lack of functional V2Rs, AQP2
does not traffic to the plasma membrane and is substantially
downregulated in X-linked NDI (X-NDI) patients and
X-NDI mice.13–16 As a consequence of the lack of AQP2
regulation, water reabsorption in the CD is severely impaired
resulting in the production of large volumes (430ml/kg/
day) of dilute urine (o250mOsm/kg) (polyuria) and
compensatory polydipsia. The main clinical characteristics
of NDI include hypernatremia, hyperthermia, mental retar-
dation, an overall failure to thrive, and repeated episodes
of dehydration in early infancy.1 So far, a targeted curative
pharmacological therapy has not been developed for the
treatment of X-NDI. The current first-line drug combination
consists of hydrochlorothiazide (2–4mg/kg per 24 h) and
amiloride (0.3mg/kg per 24 h).17,18
Many strategies have been proposed to bypass the defec-
tive V2R signaling and restore physiological AQP2 expression
and/or trafficking.15,19–28 In the last years, our group
developed the first viable animal model of X-NDI.15 We
also showed that an prostaglandin E receptor subtype EP4
receptor agonist had a beneficial effect in X-NDI mice15 and
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that fluvastatin (FLU) induced AQP2 plasma membrane
expression in vivo, independent of V2R stimulation.24
Several studies suggest that hormones other than AVP,
such as secretin (SCT), also exhibit antidiuretic functions.29
The SCT receptor (SCTR) is a G protein-coupled receptor
(GPCR) known to couple to both Gs and Gq, with the stimu-
latory cAMP response being most prominent and sensitive.30
Of note, SCTR-null mice display mild polyuria, poly-
dipsia, distension of the renal pelvis, and reduced renal
expression of AQP2.31 The same authors showed that SCTR
is expressed in the kidney medulla,31 in agreement with
previously published data.32 However, a clear demonstration
of a direct action of SCT on AQP2 transcription and
trafficking is still missing.
Here we demonstrate that the SCTR is expressed at
the basolateral membrane of AQP2-expressing CD prin-
cipal cells, prompting us to analyze the effect of SCT
ex vivo on kidney slices and in vivo in V2R-KO mice15
(X-NDI mice).
We provide compelling evidence that SCT increases cAMP
concentrations in CD tubule suspensions and promotes
AQP2 apical expression in kidney slices. In X-NDI mice,
chronic infusion with SCT increases AQP2 abundance but
not its apical expression. Of note, in SCT-infused X-NDI
mice, a single injection of FLU, a drug that induces AQP2
membrane accumulation in wt C57BL/6 mice,24 promotes
AQP2 membrane expression and greatly improves the urine
concentration ability.
RESULTS
SCTR expression in mouse and human kidney
We first used reverse transcriptase-PCR (RT-PCR) to evaluate
the presence of SCTR transcripts in different regions of the
mouse kidney. SCTR expression was clearly detectable in total
RNA samples extracted from mouse inner medulla (IM),
outer medulla (OM), and cortex (CTX; Figure 1a). Sequen-
cing confirmed the specificity of the obtained bands (data not
shown).
We next examined SCTR protein expression in mouse
kidney by western blotting. Total protein extracts from IM,
OM, and CTX were analyzed, along with protein extracts
from mouse brain, cerebellum, liver, heart, and pancreas,
all tissues expressing SCTR. A protein band of the expected
molecular mass (52 kDa) was immunodetected in all samples.
SCTR expression was more abundant in the kidney OM and
CTX compared with the IM (Figure 1b). The specificity
of the band obtained with the anti-SCT affinity-purified
antibody (Ab) was tested by pre-adsorbing the Ab with the
immunizing peptide (Figure 1b).
Unfortunately, we could not perform SCTR immuno-
localization studies in mice as the SCTR Ab, which was raised
against a synthetic peptide corresponding to the human
SCTR sequence, proved unsuitable for immunofluorescence
studies in mouse kidney. On the other hand, we carried out
SCTR immunolocalization studies in human kidney sections
from kidney CTX using the same Ab. Sections were stained
with the anti-SCTR Ab and co-stained with anti-AQP2,
AQP3, and Naþ /Kþ -ATPase Abs, after which images were
obtained with laser confocal-scanning microscopy. Figure 2a
shows that SCTR fluorescence specifically decorated the
basolateral membrane of AQP2-positive cells. In particular,
we colocalized SCTR with two basolateral markers: AQP3
and Naþ /Kþ -ATPase. Confocal analysis indicated a signi-
ficant degree of colocalization of SCTR with both basolateral
membrane markers (Figure 2a and b, overlay, 3 magni-
fication insets).
SCTR staining was also detected in other kidney tubules
that were not stained by the anti-AQP2 Ab. We were also able
to identify SCTR staining in the Tamm–Horsfall-positive
tubule, thus strongly indicating that, besides the CD system,
SCTR is also expressed in the thick ascending limb of Henle’s
loop within the kidney (Figure 2c). Of note, being both anti-
SCTR and anti-THP Abs produced in rabbit, we used two
sequential human kidney sections.
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Figure 1 | Analysis of the expression of secretin receptor (SCTR)
in the mouse kidney by reverse transcriptase-PCR (RT-PCR)
and western blotting. (a) Total RNAs extracted from kidney inner
medulla (IM), outer medulla (OM), cortex (CTX), and pancreas
were probed for the presence of mRNA encoding SCTR. Specific
bands were obtained in all kidney fractions. Control RT-PCR was
performed using primers amplifying mouse beta-actin mRNA.
Three independent experiments were carried out. (b) Total protein
extract from mouse kidney IM, OM, and CTX, were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotted for the presence of SCTR. Mouse
brain, cerebellum, liver, heart, and pancreas were used as additional
controls. The specificity of the immunodetected band was
demonstrated using anti-SCTR antibodies pre-adsorbed on the
immunizing peptide. Three independent experiments were
carried out.
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SCTR is functionally expressed in mouse kidney and
regulates AQP2 exocytosis via cAMP increase
We next incubated freshly isolated mouse inner medullary
CD (IMCD) suspensions with either 1-deamino-8-D-arginine-
vasopressin (dDAVP) or SCT and measured changes in
intracellular cAMP concentrations. Treatment with either
SCT or dDAVP led to concentration-dependent increases in
intracellular cAMP levels in wt mice (Figure 3a, wt mice). The
magnitude of the dDAVP-mediated cAMP response was greater
than that of the corresponding SCT response. In addition, SCT
was also able to increase cAMP concentration in IMCD suspen-
sion isolated from X-NDI mice (Figure 3a, X-NDI mice).
Next, we stimulated SCTR with its physiological ligand
SCT in mouse kidney slices in vitro. Interestingly, 10 7mol/l
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Figure 2 | Immunolocalization of secretin receptor (SCTR) in human kidney sections. Immunofluorescence detection of SCTR in
human kidney. (a) SCTR was stained with Alexa Fluor-555 (red), aquaporin 2 (AQP2) was stained with Alexa Fluor-488 (green), and Naþ /
Kþ -ATPase with Alexa Fluor-633 (blue). AQP2 was seen at the apical pole of the collecting duct (CD) principal cells, whereas the SCTR
antibody decorated the basolateral membrane of the same cells and colocalized with the basolateral marker Naþ /Kþ -ATPase (pink color
in the 3 magnified signal). (b) SCTR was stained with Alexa Fluor-488 (green), AQP3 was stained with Alexa Fluor-555 (red), tissue
counterstained with TO-PRO (blue). SCTR largely colocalized with AQP3 at the basolateral membrane of CD cells (yellow color in the 3
magnified signal). (c) Co-immunostaining in serial sections using AQP2 (green) as marker of the CD and Tamm–Horsfall protein (THP, red)
as marker of the thick ascending limb (TAL). SCTR-positive tubules (asterisks) were also positive for THP. Magnification 60.
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of SCTwas as effective as 10 7mol/l of dDAVP in promoting
AQP2 trafficking toward the luminal plasma membrane
when compared with the cytoplasmic localization of AQP2
observed in control slices (Figure 3b). Quantification of the
relative extent of dDAVP- and SCT-stimulated AQP2
translocation is shown in Figure 3c. Plasma membrane
translocation was determined by visualization on a Leica SP2
confocal microscope analyzing 4100 randomly chosen CD
principal cells per condition. The number of cells displaying a
complete redistribution of the staining toward the apical
plasma membrane was calculated as a percentage of all
counted cells and expressed as means±s.e. from three
independent experiments.
We observed clear AQP2 apical accumulation in about
90% of the cells observed both in the CTX and in the
medulla.
Characterization of NDI phenotype of V2Rfl/yEsr1-Cre mice
and effect of SCT infusion on urinary parameters
We previously described the first viable mouse model of
X-NDI.15 In these mutant mice, the V2R gene can be deleted
in a conditional (tamoxifen (TMX)-dependent) manner
in the kidneys of adult mice. The resulting V2R-KO mice
(X-NDI mice) show all key symptoms of X-NDI, including
the production of large amounts of dilute urine (polyuria)
and polydipsia.15 Eight-week-old V2Rfl/yEsr1-Cre mice
(littermates) were placed into metabolic cages, and 24-h
urine volume and osmolality, along with water intake and
body weight, were measured daily for a period of 13 days.
The resulting data are reported in Supplementary Figure 1
online. After 2 days of acclimatization to the new environ-
ment (days –2, –1), on day 0 half of the mice received a single
daily intraperitoneal (i.p.) injection of 4-hydroxytamoxifen
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Figure 3 | Effect of treatment with secretin (SCT) and dDAVP on cyclic adenosine monophosphate (cAMP) concentrations and AQP2
plasma membrane localization on kidney collecting ducts. (a) SCT and dDAVP-induced cAMP production in mouse inner medullary
collecting duct (IMCD) tubule suspensions. Freshly isolated IMCD tubule suspensions from C57BL/6 WT or tamoxifen (TMX)-induced X-linked
nephrogenic diabetes insipidus (X-NDI) mice (12-week-old males; n¼ 8 per individual experiment) were pooled and equally distributed into
24-well plates. Samples were treated with the indicated concentrations of dDAVP or SCT for 60min at 37 1C. Total cAMP generated in each
well was normalized to the amount of protein present in each well. Three independent experiments were carried out. Data are provided as
mean±s.e.m. (b) Indirect immunofluorescence images of kidney tissue slices showing AQP2 in principal cells of collecting ducts (CDs).
One C57BL/6 WT mouse kidney was cut into thin slices and incubated in vitro with buffer alone (control) or with dDAVP 10 7mol/l or SCT
10 7mol/l for 1 h before fixation by immersion, sectioning, and immunostaining to detect AQP2. Under control conditions, AQP2 was
mainly localized throughout the cytoplasm and showed little apical membrane staining in CDs. In the presence of dDAVP or SCT, AQP2 staining
of the apical membrane region was increased in principal cells of the cortical CD. The images are representative of three independent
experiments. (c) Quantification of the number of cells displaying plasma membrane (PM) localization was determined by counting the fraction
of cells showing apical PM localization. The extent of translocation is expressed as the percentage (means±s.e.) of cells showing a continuous
apical PM localization in at least 100 randomly chosen CD principal cells from three independent determinations. Quantitation of cells
displaying AQP2 apical membrane expression expressed as a percentage of total cells observed. ***Po0.0005 with Student’s t-test.
dDAVP, 1-deamino-8-D-arginine-vasopressin.
130 Kidney International (2014) 86, 127–138
bas i c resea rch G Procino et al.: Combination of secretin and fluvastatin in X-NDI
(4-OH)-TAX (0.5mg per mouse) for the following 6 days.
As reported previously,15 TMX treatment triggered marked
increases in diuresis and water intake, accompanied by a
pronounced reduction in urine osmolality (Supplementary
Figure 1 online). We did not observe significant changes in
the severity of the NDI phenotype up to 6 months after TMX
treatment (data not shown).
A detailed western blotting analysis of AVP-regulated
renal aquaporins (AQP2, 3) expressed in the kidney CTX,
OM, and IM is reported in Supplementary Figure 2
online. This analysis was performed on V2Rfl/yEsr1-Cre mice
20 and 60 days after the suspension of TMX treatment
and the western blot data were compared with those of
non-induced animals. Strikingly, in the TMX-treated mice,
we observed a marked downregulation of AQP2 and
AQP3 in all kidney portions that were investigated (Supple-
mentary Figure 2 online), in line with previously reported
data.15
Given the in vitro effects of SCT on AQP2 trafficking
as described above, we next examined whether infusion
of X-NDI mice with SCT was able to promote AQP2
expression and plasma membrane translocation. For these
experiments, we used V2Rfl/yEsr1-Cre mice 5 months after
TMX induction. Unfortunately, a single injection of SCT
at physiological doses (nanomolar) failed to produce any
effect on mice diuresis or urine osmolality (data not shown).
Given the short half-life of SCT33 and the marked
downregulation of AQP2 in X-NDI mice, we opted for a
continuous infusion for longer times. Six mice were
subcutaneously implanted with osmotic minipumps (Alzet)
loaded with a SCT solution and continuously infused for
14 days at a SCT dose of 1 nmol/kg/day at constant rate
(þ SCT). Control animals (n¼ 6, littermates) received
minipumps loaded with saline alone ( SCT). Diuresis,
urine osmolality, and water intake were recorded daily for the
entire duration of the treatment. Diuresis and urine
osmolality did not significantly change in SCT-treated
animals (Figure 4a). At the end of the studies, the animals
were killed and kidneys were used for real-time RT-PCR,
western blotting, and immunofluorescence analysis reported
in Figure 4b, c, and d, respectively.
Total kidney homogenates from TMX-induced V2Rfl/y
Esr1-Cre mice (X-NDI mice), treated or not with SCT, and
V2Rfl/yEsr1-Cre littermates that had not received TMX
(control, CTR) were used for quantitative RT-PCR and
immunoblotting with anti-AQP2 Ab. Real-time RT-PCR
indicated that SCT infusion alone doubled AQP2 gene
transcription levels compared with those in saline-infused
animals (Figure 4b). In Figure 4c, a lysate of wt mice IM (ms.
IM) was loaded in the first lane as positive control for AQP2
immunodetection. The strong signal detected in this fraction,
compared with all the whole-kidney preparations, is due to
the high abundance of AQP2 in the IM of wt mice. Interest-
ingly, semiquantitative analysis showed that AQP2 abun-
dance was increased by 90% in SCT-infused animals
(þ SCT) compared with saline-infused animals ( SCT,
Figure 4c). AQP3 expression was unchanged after SCT
infusion (data not shown).
Immunofluorescence analysis of contralateral kidney
sections supported the results obtained by western blotting:
the number of AQP2-positive tubules was clearly increased
and AQP2 fluorescent signal was clearly brighter as compared
with that of saline-infused animals (Figure 4c). However, at a
higher magnification (Figure 4c, magnified), AQP2 was
mainly localized within the cell cytoplasm with negligible
expression at the apical plasma membrane.
Association of SCT and FLU improves urinary parameters in
X-NDI mice
We previously reported that the treatment of wt mice
with FLU induced a transient accumulation of AQP2 at
the apical membrane of the CD principal cells and
increased water reabsorption in an AVP-independent
manner.24 We therefore examined the ability of FLU to pro-
mote AQP2 membrane localization in SCT-infused V2Rfl/y
Esr1-Cre mice. Mice were treated as above with SCT-
loaded osmotic minipumps, except that half of both the
SCT and control groups received a single i.p. injection
of FLU (50mg/kg) on the last day of SCT treatment.
The other half of animals was injected with the same
volume of saline solution. We measured cumulative urine
output and urine osmolality for 6 h following FLU injection
(Figure 5).
Strikingly, urine production of SCT-infused animals that
had received FLU was reduced by nearly 90% as compared
with both untreated and SCT-treated animals (Figure 5,
SCTþ FLU). SCT alone had no effect on diuresis, in agree-
ment with experiments shown in Figure 4a, whereas FLU
alone had a small but significant effect. Moreover, urine
osmolality was significantly increased (B2-fold) in the
SCT-infused mice that had received FLU. Blood was taken
for sinistrin-fluorescein isothiocyanate clearance determina-
tions (see Materials and Methods section) and estimation of
glomerular filtration rate (GFR). GFR of SCTþ FLU-infused
mice was 317.3±14.89 ml/min, which was statistically higher
than that of saline-infused animals (218.3±9.28 ml/min) as
reported in Table 1.
At the end of the treatment, X-NDI mice were killed and
the immunolocalization of renal AQP2 was examined by
immunofluorescence (Figure 6). Non-induced animals were
analyzed in parallel (top panels).
The most striking difference between non-induced
( TMX) and TMX-induced (þ TMX) X-NDI mice was
the abundance of AQP2 in all kidney portions examined. In
fact, in TMXþ X-NDI mice, AQP2-positive CDs were rare
and poorly immunoreactive to AQP2 Abs compared with
TMX–animals (Figure 6, CTR). In FLU-injected X-NDI mice,
the low residual AQP2 was localized to the apical plasma
membrane (Figure 6, Flu). SCT infusion for 14 days clearly
increased the number and the immunoreactivity to AQP2 Ab
of CDs (Figure 6, SCT). However, observation of kidney
CDs at higher magnification clearly indicated that AQP2 was
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localized mainly intracellularly (Figure 6, SCT, inset).
Remarkably, after FLU treatment in SCT-infused mice,
AQP2 was predominantly expressed at the apical plasma
membrane (Figure 6, SCTþ Flu).
DISCUSSION
In this study, we provide strong evidence that combined
administration of SCT and FLU increases AQP2 plasma
membrane expression in X-NDI mice and improves the
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Figure 4 | Effect of prolonged infusion of X-linked nephrogenic diabetes insipidus (X-NDI) mice with secretin (SCT) on urine output,
urine osmolality, aquaporin 2 (AQP2) abundance, and membrane expression. (a) Five months after the end of the tamoxifen (TMX)-
injection period, X-NDI mice were subcutaneously implanted with osmotic minipumps and continuously infused with saline alone or SCT at a
dose of 1 nmol/kg/day over a 14-day period. Urine output, normalized for body weight, and osmolality were measured daily. No significant
changes in urinary parameters were seen in SCT-infused animals. (b) At the end of the experiment, quantitative reverse transcription
polymerase chain reaction was performed on kidneys from X-NDI infused with saline ( SCT) or with secretin (þ SCT). Control animals that did
not receive TMX were included (CTR). Relative quantification of gene expression (RQ) was performed setting the amount of AQP2 mRNA in
vehicle-infused animals ( SCT) as 1. SCT-infused animals exhibited an approximately twofold increase in AQP2 gene transcription compared
with saline-infused mice. (*Po0.05, **Po0.005, ***Po0.0005 with Student’s t-test, n¼ 6 per group.) (c) Western blotting with anti-AQP2
antibodies was carried out using homogenates prepared from whole left kidneys. Kidneys from control animals of the same age that had not
received TMX were used as control. Protein extract from mouse inner medulla (IM) was loaded as positive control for AQP2 immunodetection.
29 kDa AQP2 band (AQP2) and glycosylated AQP2 band (gly) are indicated. Densitometric analysis of AQP2 bands, normalized for the actin
abundance in each fraction, is reported on the right indicating that SCT infusion promoted a nearly 90% increase of AQP2 abundance. (d) The
right kidneys were subjected to immunofluorescence localization of AQP2 in the three kidney regions. The number of AQP2-positive CD cells
and the intensity of AQP2 fluorescence were increased in SCT-infused animals. Observation of single tubules at higher magnification (right
panels) unambiguously showed that AQP2 was localized intracellularly. The experiment was repeated three times and comparable results were
obtained. *Po0.05; ***Po0.0001; N¼ 6 per group.
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kidney concentration defect of these animals. X-NDI is
characterized not only by the lack of plasma membrane
trafficking of AQP2 but also by a severe downregulation
of AQP2 protein expression. Both phenomena result from
the inactivation of V2R signaling in the principal cells of
the CDs. Consequently, strategies aimed at correcting the
described AQP2 deficits may offer novel therapeutic
opportunities for X-NDI therapy.
One possible approach to bypass V2R function in the
CD principal cells is to activate other GPCRs coupled to
Gs/adenylyl cyclase. We already showed that a compound
that selectively activates the prostaglandin E receptor subtype
EP4 is highly effective in ameliorating all major manifesta-
tions of X-NDI.15 Here we investigated the presence and the
activity of SCTR in the mouse and human CD and its
possible role in regulating AQP2 expression and trafficking.
We previously reported a detailed analysis of the GPCRs
expressed by IMCD cells.15 Interestingly, several GPCRs
expressed by IMCD cells (Gpr56, Gpr116, Gpr125, and
Gpr97) belong to the SCT-like family-2 of GPCRs, although
the endogenous ligands have not been identified for these
receptors. Another piece of evidence, supporting the presence
of SCTR in the CDs and its possible role in regulating AQP2,
comes from the work of Chu et al.31 who reported that
SCTR / mice show reduced renal expression of AQP2,
associated with mild polyuria and polydipsia. The possible
involvement of SCT in regulating water reabsorption in
the kidney via AQP2 membrane expression is also suggested
by the observation that SCT plasma levels are increased
during water deprivation in normal rats but not in hypo-
physectomized animals.21
In this study, we show by western blotting that the Gs-
coupled SCTR is expressed in the mouse kidney in the CTX,
OM, and IM. We also performed immunolocalization studies
of SCTR in human kidney sections and clearly showed,
for the first time, that SCTR is localized to the basolateral
membrane of AQP2-expressing cells and in the thick
ascending limb. The observation that SCTR is expressed in
the kidney CDs is essential for attempts to target this receptor
for therapeutic purposes in X-NDI patients lacking proper
V2R function.
We also report that, ex vivo, short-term SCT stimulation of
the SCTR induced a dose-dependent rise in intracellular
cAMP concentrations in the CDs and in AQP2 translocation
from intracellular vesicles to the plasma membrane in freshly
isolated kidney slices from CTR and X-NDI mice.
To explore the potential usefulness of SCT for the therapy
of X-NDI, we treated X-NDI mice with SCT. As the estimated
half-life of circulating SCT is very short (1.5–5min),33 and
single injection had no effect in our experimental model, we
delivered SCT continuously in the systemic circulation using
osmotic minipumps. Exogenous SCT was infused at the rate
of 1 nmol/kg/day, comparable to rates previously reported by
other authors,34,35 and was able to increase the SCT plasma
concentration above the physiological range.35 The most
striking effect of SCT infusion was the upregulation of AQP2
mRNA and protein expression in the kidneys of X-NDI mice.
Unfortunately, the increased expression of AQP2 per se was
insufficient to ameliorate the X-NDI phenotype, as AQP2
remained intracellular.
The effects evoked by short- and long-term stimulation of
SCTR on AQP2 trafficking and expression may seem to be in
apparent contradiction to each other. However, it is not
surprising that stimulation of GPCR with a persistent ligand
is followed by several distinct mechanisms of desensitization
that attenuate receptor signaling.
Table 1 | FE of Naþ and Kþ and GFR measured in control
X-NDI mice (CTR) and in animals after the combined
treatment with SEC and FLU (SCTþ FLU)
CTR SCTþ FLU
FENa% 0.7933±0.05812 0.2333±0.03528**
FEK% 34.20±1.562 17.60±1.058***
GFR (ml/min) 218.3±9.280 317.3±14.89**
Abbreviations: FE, fractional excretion; FLU, fluvastatin; GFR, glomerular filtration
rate; SCT, secretin; X-NDI, X-linked nephrogenic diabetes insipidus.
**Po0.05; ***Po0.001.
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Figure 5 | Combination of prolonged secretin (SCT) infusion
and a single fluvastatin (FLU) injection markedly ameliorates
nephrogenic diabetes insipidus (NDI) symptoms in X-linked NDI
(X-NDI) mice. Five months after the end of tamoxifen (TMX)-injection
period, X-NDI mice were subcutaneously implanted with osmotic
minipumps and continuously infused with either saline alone or SCT
at a dose of 1 nmol/kg/day over a 14-day period. On the last day
of SCT infusion, half of the control and SCT-infused mice were given
an intraperitoneal (i.p.) injection of FLU (50mg/kg) and urine output
and osmolality were monitored for the following 6 h. Compared
with untreated animals (CTR), FLU alone had a slight effect on urine
output and urine osmolality. As already shown in Figure 4, SCT alone
had no significant effect on urinary parameters. Interestingly, a single
FLU injection in SCT-infused mice (SCTþ FLU) led to a marked
reduction of urine output, accompanied by a significant increase
of urine osmolality. Data are presented as mean±s.e.m. **Po0.05;
***Po0.001. N¼ 5 per group.
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At present, we do not have an explanation for the lack
of AQP2 plasma membrane expression observed after
prolonged (14 days) stimulation with SCT, but SCTR
desensitization may have a role in this phenomenon. It has
been demonstrated that SCTR undergoes a rapid desensitiza-
tion within minutes after exposure to its ligands to prevent
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Figure 6 | Combination of prolonged secretin (SCT) infusion and a single fluvastatin injection upregulates aquaporin 2 (AQP2)
expression and promotes AQP2 plasma membrane localization in X-linked nephrogenic diabetes insipidus (X-NDI) mice. At the end of
the treatment described in Figure 5, mice were killed and their kidneys subjected to AQP2 immunolocalization followed by confocal
examination. V2Rfl/yEsr1-Cre mice of the same age that had not received tamoxifen ( TMX) were analyzed in parallel. Random pictures were
taken in the kidney cortex, outer medulla, and inner medulla. A high magnification of a detail of each image is shown in the upper left corner of
each panel. Compared with non-induced animals ( TMX, CTR), mice with V2R deletion (þ TMX, CTR) showed a marked reduction of AQP2
immunoreactivity in each kidney portion. FLU injection triggered the accumulation of the remaining amount of AQP2 on the luminal
membrane. SCT infusion greatly upregulated AQP2 immunoreactivity in the kidney collecting ducts (CDs). At higher magnification, AQP2 was
seen mainly in the cytoplasm with negligible plasma membrane expression. In mice chronically infused with SCT and injected with fluvastatin
(SCTþ FLU), AQP2 was upregulated and mainly expressed at the luminal membrane of CD tubules. Representative images are shown
(N¼ 5). G, glomerulus.
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cellular overstimulation.36–38 We can hypothesize that the
residual SCTR activity may be sufficient for boosting AQP2
transcription but too low to induce AQP2 membrane expres-
sion. Recent work with the mpkCCD mouse cell line has shown
that the long-term regulation of AQP2 by AVP occurs indepen-
dent of protein kinase A and cAMP-responsive element-binding
protein, but may involve the exchange factor directly activated
by cAMP (Epac).39 In particular, these authors demonstrated
that after 4 days of dDAVP stimulation, cAMP intracellular
concentrations are lower than those measured after 30min or
1 day of stimulation, although AQP2 levels were still sustained.
On the basis of these observations, prolonged stimulation of
SCTR in mouse kidney may result in similar long-term effects:
cAMP responses may become partially blunted, leading to
impairment in protein kinase A activation and AQP2 exo-
cytosis. At the same time, Epac activation may be sufficient to
sustain AQP2 transcription. Such a mechanism would explain
our findings that AQP2 is upregulated but shows a preferential
cytoplasmic localization in SCT-infused X-NDI mice.
We previously reported that FLU treatment leads to
translocation of AQP2 in vivo in wt mice.24 We show here
that FLU treatment alone has a slight effect on the urine
concentrating ability of X-NDI mice, most likely due to the
very low levels of AQP2 expressed by these mutant mice.
Strikingly, however, FLU treatment of SCT-infused X-NDI
mice led to a marked reduction of the diuresis with no
impairment of the GFR (Table 1).
The fact that in SCTþ FLU-treated mice urine volume is
reduced by 90%, whereas urine osmolality only doubles may
also indicate that solute reabsorption is increased in kidney
tubules by this combined treatment. An additional possible
target of SCTaction may be the thick ascending limb of Henle’s
loop and in particular the cotransporter NKCC2.40 We showed
here by immunofluorescence that SCTR is also expressed in the
thick ascending limb. We also showed that in X-NDI mice,
following the combination of SCT and FLU, the fractional
excretion of Naþ and Kþ was significantly reduced (Table 1),
thus suggesting that increased solute reabsorption is promoted
in these mice in which the cortico-medullary osmotic gradient
is compromised in the absence of V2R signaling. Further
investigation is needed to address this interesting aspect.
We recently showed the proof of principle that high doses
of FLU can increase AQP2 plasma membrane expression in
the kidney CDs of wt mice.24 We also identified some of the
intracellular targets of statins that could explain the effect on
AQP2 membrane expression and hypothesized that reduced
prenylation of RhoA and Rab5 may explain AQP2 membrane
accumulation.24 Consistent data were also obtained on
Brattleboro rats infused with simvastatin.22 These observa-
tions imply that different drugs, acting downstream of the
cholesterol biosynthetic pathway step inhibited by statins, in
particular inhibitors of geranylgeranyl transferases,41 may be
useful as regulators of AQP2 trafficking. Alternatively, the
development of new classes of statins with prolonged half-life
and preferential kidney delivery may allow the use of much
lower doses of these agents for the treatment of X-NDI.
It should be noted that recombinant SCT is already
approved for use in humans in the diagnosis of gastro-
intestinal disorders and FLU is Food and Drug Administra-
tion approved for clinical use since 1993.
In conclusion, we have shown that prolonged SCT
infusion greatly rescues AQP2 protein downregulation in
X-NDI mice. In addition, FLU treatment of SCT-infused
X-NDI mice effectively promotes AQP2 membrane accumu-
lation, resulting in a marked reduction in urine output. We
hypothesize that SCT stimulation alone activates an intra-
cellular pathway leading to AQP2 gene transcription with
no apparent effect on membrane trafficking. FLU shows a
pleiotropic effect on plasma membrane accumulation of
AQP2. The combination of the two molecules also increases
solute conservation/reabsorption, thus providing the osmotic
gradient for water reabsorption.
These results are highly relevant for the development of
novel pharmacological approaches for the treatment of
human X-NDI. In particular, a combination of molecules
that can increase AQP2 transcription and plasma membrane
targeting may improve the beneficial effects of the current
therapy and further reduce the polyuria of NDI patients with
a positive impact on their quality of life.
MATERIALS AND METHODS
Abs and reagents
Rabbit polyclonal affinity-isolated Abs against actin and SCTR
(cat.# HPA007269), collagenase (cat.# C0130), and hyaluronidase
(cat.# H3506) were from Sigma (www.sigmaaldrich.com). Goat
anti-AQP3, goat anti-Naþ /Kþ -ATPase, rabbit anti-Tamm-Horsfall,
and mouse anti-AQP2 Abs were from Santa Cruz Biotechnology
(www.scbt.com). Rabbit affinity-purified polyclonal Abs against
human AQP2 were previously described.10 dDAVP and 4-OH-TAX
were purchased from Sigma, and rat SCT from Chiscientific
(www.chiscientific.com). FLU sodium salt was purchased from
Sequoia Research Products (www.seqchem.com).
RNA isolation, RT-PCR, and RT-quantitative PCR
Total RNA was extracted from adult mouse kidney and pancreas by
the TRIzol extraction method (TRIzol reagent, Life Technologies,
Invitrogen, Carlsbad, CA). The RNA was then used to amplify
fragments of the complementary DNA of the AQPs using Super-
Script VILO cDNA Synthesis Kit One-Step RT-PCR (Life Techno-
logies). The primers (forward: 50-ACCTGCTGAAGCTCAAGGC-30,
reverse: 50-GTCATCTGCGGGGAAGAGTA-30) were designed on
the basis of the mus musculus SCTR nucleotide sequences available
in the GenBank database (web site: http://www.ncbi.nlm.nih.gov/
nuccore). The primers pair was chosen to hybridize with comple-
mentary DNA sequences derived from different exons (6 and 7),
thereby excluding those amplimers arising from genomic DNA
contamination. A positive control was performed by using primers
specific for mouse b-actin complementary DNA. PCRs were
performed with the following program:
(94 1C, 5min)1 cycle;
(94 1C, 45 s; 59 1C, 30 s; 72 1C, 30 s)40 cycles.
The PCR products were separated on a 3% agarose gel and were
visualized with ethidium bromide.
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For quantification of AQP2 mRNA, total RNA was extracted
using Trizol (Invitrogen). RNAwas reverse transcribed and real-time
PCR was performed in triplicate using the Applied Biosystems
StepONE Real-time PCR system and TaqMan GenExpression Assays
(Life Technologies, part no.:4331182) for mouse AQP2 (Life
Technologies, Mm 00437575 Aqp2_m1). Mouse glyceraldehyde
3-phosphate dehydrogenase (Life Technologies, Mm 99999915_g1)
was used as endogenous control. Each reaction was carried on as
a singleplex reaction. The setup of reactions consisted of 1 ml of
complementary DNA (20 ng), 1 ml of TaqMan Gene Expression
Assay Mix, part no.: 4351370, 10ml TaqMan Gene Expression Master
Mix, catalog no.: 4369016, and 8 ml of Rnase-free water under the
following PCR conditions: step 1, 95 1C for 10min; step 2, 95 1C for
15 s; and step 3, 60 1C for 1min; steps 2 and 3 were repeated
40 times.
The relative quantification of target gene expression was evalu-
ated with data from the Step-ONE software (Foster City, CA), using the
arithmetic formula 2–DDCt, according to the comparative Ct method,
which represents the amount of target, as normalized to the glyceral-
dehyde 3-phosphate dehydrogenase endogenous control (reference).
Tissue fractionation and immunoblotting
Whole-kidney or kidney CTX, OM, and IM were isolated from Wt
C57BL/6 or V2Rfl/yEsr1-Cremice and homogenized using an Heidolf
tissue homogenizer (http://www.heidolph-instruments.com) at
1250 r.p.m. in 2ml RIPA buffer (150mmol/l NaCl, 10mmol/l
Tris, pH 7.2, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 1%
deoxycholate, 5mmol/l EDTA) containing protease inhibitors
(1mmol/l phenylmethylsulfonyl fluoride, 10mmol/l leupeptin,
1 mg/ml pepstatin, 10mmol/l NaF, 1mmol/l sodium orthovanadate,
and 15mmol/l tetrasodium pyrophosphate). Unbroken cells and
nuclei were pelleted by centrifugation at 13, 000g for 30min at
4 1C. An amount of 30 mg of each supernatant was separated by
standard sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and analyzed by western blotting.
Protein samples, diluted in Laemmli’s buffer with 50mmol/l
dithiothreitol, were heated for 10min at 60 1C, resolved on 12%
sodium dodecyl sulfate-polyacrylamide gels, and then electro-
phoretically transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA) for western blot analysis.
After blocking with 3% bovine serum albumin in tris buffer
saline-tween 20, blots were incubated overnight at 4 1C with the
indicated primary Abs. Membranes were washed and incubated with
horseradish peroxidase–conjugated secondary Abs. Reactive proteins
were revealed with an enhanced chemiluminescent detection
system (SuperSignal West Pico Chemiluminescent Substrate, Pierce,
Rockford, IL) and chemiluminescence was detected with Chemidoc
XRS detection system equipped with Image Lab Software for image
acquisition (www.bio-rad.com).
The quantification of protein bands was performed by
determination of the relative optical density using ImageJ software
(National Institutes of Health, Bethesda, MD).
Abs and their corresponding dilutions were: mouse anti-actin
(1:500, Sigma Aldrich), mouse anti-SCTR (1:300, Sigma Aldrich),
goat anti-AQP3 (1:500, Santa Cruz Biotechnology), and rabbit anti-
AQP2 (1:1000, affinity-purified Ab10).
Immunofluorescence
Mouse kidneys were fixed overnight with 4% paraformaldehyde at
4 1C, cryopreserved in 30% sucrose for 24 h, and then embedded in
optimal cutting temperature medium. Ultrathin sections (4 mm)
placed on Superfrost/Plus Microscope Slides (Thermo Scientific,
Braunschweig, Germany) were subjected to immunofluorescence
analysis. Nonspecific binding sites were blocked with 1% bovine
serum albumin in phosphate-buffered saline (PBS) (saturation
buffer) for 30min at room temperature. Sections were then incu-
bated with the primary Abs for 2 h at room temperature (dilutions:
AQP2 affinity purified 1:1000; monoclonal AQP2 1:250; SCTR
1:300; THP 1:500; Naþ /Kþ -ATPase 1:1000) in saturation buffer.
After washing in PBS, sections were incubated with the appropriate
AlexaFluor-conjugated secondary Ab (www.lifetechnologies.com)
for 1 h at room temperature. After washing in PBS, sections were
incubated with TO-PRO-3 Iodide (642/661) (1:10, 000 in PBS,
Life Technologies) for 10min and were mounted in PBS/glycerol
(1:1) containing 1% n-propylgallate, pH 8.0. Confocal images were
obtained with a confocal laser-scanning fluorescence microscope
(Leica TSC-SP2, Mannheim, Germany).
In situ kidney tissue slices: preparation and treatment
The effect of SCT on AQP2 trafficking was studied in thin kidney
slices prepared from C57BL/6 mice.
Briefly, adult male mice were anesthetized with an i.p. injection
of tribromoethanol (250mg/kg; Sigma Aldrich) and killed by
cervical dislocation. Kidneys were rapidly excised and thin
transversally sliced kidneys (250 mm) were cut using a McILWAIN
Tissue Chopper (Ted Pella, http://www.tedpella.com).
All of the slices were incubated at 37 1C for 15min in
equilibrated Dulbecco’s modified Eagle’s medium-F12 medium
only. After equilibration, the slices were distributed into a multiwell
plate containing either Dulbecco’s modified Eagle’s medium-F12 or
dDAVP (10 7mol/l) or SCT (10 7mol/l) in Dulbecco’s modified
Eagle’s medium-F12. After 60min of incubation at 37 1C, all of the
slices were fixed by immersion in 4% paraformaldehyde in PBS at
4 1C overnight. The slices were then rinsed several times in PBS
before use for immunostaining as described above. The immuno-
fluorescence protocol was the same but slices were incubated with
saturation buffer and primary Ab overnight at 4 1C.
Preparation of IMCD tubule suspensions
IMs were dissected out from kidneys of C57BL/6 WT mice (10-
week-old males), minced, and enzymatically digested in Dulbecco’s
modified Eagle’s medium-F12 high glucose containing 0.3%
collagenase and 0.3% hyaluronidase at 37 1C for 90min. The
resulting suspension was centrifuged at 80 g for 30 s. IMCD-enriched
pellets were collected after three washes with medium culture to
remove residual proteases.
cAMP assays
cAMP assays were performed using mouse IMCD tubule suspen-
sions, which were prepared as described above. For each individual
experiment, IMCD suspensions were prepared and pooled from the
kidneys of seven C57BL/6 WT and X-NDI mice (12-week-old
males). Aliquots of IMCD tubule suspensions were preincubated
with the cAMP phosphodiesterase inhibitor 3-isobutyl-1-methyl-
xanthine for 10min at 37 1C.
Subsequently, different concentrations of SCT (10 8mol/l to
10 5mol/l) or dDAVP (10 9mol/l to 10 6mol/l) were added, and
reactions were carried out for 30min at 37 1C. Total intracellular
cAMP was determined via enzyme-linked immunosorbent assay
according to the manufacturer’s instructions (cAMP Biotrak; GE
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Healthcare, Buckinghamshire, UK). cAMP data were analyzed using
Prism software (version 4.0; GraphPad Software, La Jolla, CA).
Animal studies
All animal experiments carried out were approved by the
Institutional Committee on Research Animal Care, in accordance
with the Italian Institute of Health Guide for the Care and Use of
Laboratory Animals.
Mice were maintained on a 12-h light/12-h dark cycle, with free
access to water and food.
Wt C57BL/6 mice (Harlan Laboratories (Indianapolis, IN),
males, 8-week old) were used to obtain kidney slices.
The generation of conditional V2R mutant mice (V2Rfl/fland
V2Rfl/yEsr1-Cre mice) has been described previously.15 To disrupt
the V2R gene in V2Rfl/yEsr1-Cre mice and to induce the X-NDI
phenotype, a stock solution of 4OH-TMX (Sigma), prepared in
preheated ethanol (50mg/ml), was diluted in corn oil to 5mg/ml.
Adult V2Rfl/yEsr1-Cre mice (age 7–8 weeks old) were given a daily
i.p. injection of 4-OH-TMX (0.1ml of a 5mg/ml suspension) over
6 days.
Treatment with drugs
Animals were treated with SCT and/or FLU 5 months after the
last TMX injection. Rat SCT was administered subcutaneously
(1 nmol/kg/day) to X-NDI mice via an Alzet (www.alzet.com)
osmotic pump model 1002 implanted in a pocket between the
scapulae under anesthesia. The skin incision was sutured. Pumps
were loaded with a 100 ml solution of 10 mg/ml SCT in sterile PBS
and kept in place for 14 days. Control animals received pumps
loaded with PBS alone.
On the 14th day, half of the animals received a single i.p.
injection of FLU (50mg/kg). Mice were placed into metabolic cages
(Tecniplast, www.tecniplast.it). Urine output and osmolality, along
with water consumption, were monitored daily. Urine osmolalities
were measured using a vapor pressure osmometer (model 5520;
Wescor, www.wescor.com).
Mice were anesthetized with tribromoethanol (250mg/kg; Sigma
Aldrich) and killed by cervical dislocation.
Urinary and plasma creatinine were measured by high-perfor-
mance liquid chromatography following a protocol similar to that
described by Procino et al.24
Determination of glomerular filtration rate
GFR of conscious mice was measured by fluorescein isothiocyanate-
labeled sinistrin clearance after a single retro-orbital injection and
consecutive blood sampling from the tail vein.42
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